
    
      Adult patients with histologically or cytologically confirmed advanced or metastatic
      cholangiocarcinoma with FGFR2 gene fusions or translocations or other FGFR genetic
      alterations who have evidence of radiologic progression following a cisplatin-and
      gemcitabine-containing regimen for advanced disease or a gemcitabine-containing regimen for
      those who are considered intolerant to cisplatin will be enrolled. Up to approximately 160
      adult patients over age 18, both male and female will be enrolled. Three cohorts of patients
      comprise the study population:

      Cohort 1: patients with FGFR2 gene fusions or translocations and other FGFR genetic
      alterations enrolled under the original protocol and amendment 1.

      Cohort 2: patients with FGFR genetic alterations other than FGFR2 gene fusions or
      translocations.

      Cohort 3: patients with FGFR2 gene fusions or translocations who have received a prior FGFR
      inhibitor.

      All patients will receive oral BGJ398, once daily, on a three weeks on (21 days), one week
      off (7 days) schedule. One treatment cycle will consists of 28 days.
    
  